These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8896454)
21. Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: co-stimulation of AP-1 and CRE nuclear binding proteins. Miller C; Zhang M; He Y; Zhao J; Pelletier JP; Martel-Pelletier J; Di Battista JA J Cell Biochem; 1998 Jun; 69(4):392-413. PubMed ID: 9620167 [TBL] [Abstract][Full Text] [Related]
22. Wilms tumor and the WT1 gene. Lee SB; Haber DA Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525 [TBL] [Abstract][Full Text] [Related]
23. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710 [TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. Huang W; Zhou X; Lefebvre V; de Crombrugghe B Mol Cell Biol; 2000 Jun; 20(11):4149-58. PubMed ID: 10805756 [TBL] [Abstract][Full Text] [Related]
25. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells. Han Y; San-Marina S; Yang L; Khoury H; Minden MD Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147 [TBL] [Abstract][Full Text] [Related]
26. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587 [TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (IRF2) in vitro and in vivo. Birnbaum MJ; van Zundert B; Vaughan PS; Whitmarsh AJ; van Wijnen AJ; Davis RJ; Stein GS; Stein JL J Cell Biochem; 1997 Aug; 66(2):175-83. PubMed ID: 9213219 [TBL] [Abstract][Full Text] [Related]
28. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Englert C; Vidal M; Maheswaran S; Ge Y; Ezzell RM; Isselbacher KJ; Haber DA Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11960-4. PubMed ID: 8618823 [TBL] [Abstract][Full Text] [Related]
29. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. McCoy C; McGee SB; Cornwell MM Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899 [TBL] [Abstract][Full Text] [Related]
30. Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. Laity JH; Dyson HJ; Wright PE Proc Natl Acad Sci U S A; 2000 Oct; 97(22):11932-5. PubMed ID: 11050227 [TBL] [Abstract][Full Text] [Related]
31. GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Liu QR; Zhang PW; Lin Z; Li QF; Woods AS; Troncoso J; Uhl GR Biochem J; 2004 Jan; 377(Pt 1):171-81. PubMed ID: 12974676 [TBL] [Abstract][Full Text] [Related]
32. The speckling domain of the Wilms tumor suppressor WT1 overlaps with the transcriptional repression domain. Herzer U; Lutz B; Hartmann K; Englert C FEBS Lett; 2001 Apr; 494(1-2):69-73. PubMed ID: 11297737 [TBL] [Abstract][Full Text] [Related]
33. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor. Tajinda K; Carroll J; Roberts CT Endocrinology; 1999 Oct; 140(10):4713-24. PubMed ID: 10499530 [TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor inhibits MRF4 activity independently of the phosphorylation status of a conserved threonine residue within the DNA-binding domain. Hardy S; Kong Y; Konieczny SF Mol Cell Biol; 1993 Oct; 13(10):5943-56. PubMed ID: 8413199 [TBL] [Abstract][Full Text] [Related]
36. The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. Morrison AA; Venables JP; Dellaire G; Ladomery MR Biochem Cell Biol; 2006 Oct; 84(5):789-98. PubMed ID: 17167543 [TBL] [Abstract][Full Text] [Related]
37. New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual study. Nurmemmedov E; Yengo RK; Uysal H; Karlsson R; Thunnissen MM Biophys Chem; 2009 Dec; 145(2-3):116-25. PubMed ID: 19853363 [TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of helix-loop-helix proteins ID1, ID2 and ID3. Nagata Y; Shoji W; Obinata M; Todokoro K Biochem Biophys Res Commun; 1995 Feb; 207(3):916-26. PubMed ID: 7864897 [TBL] [Abstract][Full Text] [Related]
39. The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Lo HW; Antoun GR; Ali-Osman F Cancer Res; 2004 Dec; 64(24):9131-8. PubMed ID: 15604283 [TBL] [Abstract][Full Text] [Related]
40. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]